Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$961.1KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark A. Emalfarb
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 1.15
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -22.41
Financials
Revenue
$961.1K+95.7%Net Income
$-2.12MEBITDA
$-2.01MFree Cash Flow
$-1.82MEPS (diluted)
$-0.06Shares Outstanding (diluted)
36.44M+0.7%Operating Expenses
$2.02MCash & Debt
$3.11MReturn of Capital
$0.00Revenue by Segment (annual)
$3.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.23M | $-7.36M | $-0.23 |
| 2024 | $3.50M | $-5.81M | $-0.20 |
| 2023 | $2.90M | $-6.80M | $-0.24 |
| 2022 | $2.93M | $-9.74M | $-0.34 |
| 2021 | $2.40M | $-13.07M | $-0.47 |
| 2020 | $1.60M | $-9.33M | $-0.34 |
| 2019 | $1.68M | $-8.31M | $-0.31 |
| 2018 | $1.30M | $-5.69M | $-0.21 |
| 2017 | $758.4K | $-2.14M | $-0.07 |
| 2016 | $592.9K | $-3.61M | $-0.10 |
| 2015 | $315.7K | $65.79M | $1.91 |
| 2014 | $12.52M | $-5.98M | $-0.18 |
| 2013 | $17.13M | $-428.1K | $-0.01 |
| 2012 | $15.60M | $1.35M | $0.04 |
Valuation
DYAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·20d ago·Positive
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.03 per share
Typical surprise -37.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.06 vs $-0.04miss
- Wed, May 13$-0.05 vs $-0.04miss
- Wed, Mar 25$-0.06 vs $-0.03miss
- Wed, Nov 12$-0.06 vs $-0.04miss
- Wed, Aug 13$-0.06 vs $-0.06beat
- Wed, Mar 26$-0.05 vs $-0.04miss
Estimates and results for DYAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DYAI officers and directors.
- Bought
- $1.0m
- Sold
- $469k
2 trades
10 trades
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Hazelton Joseph Pbought
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
- Francisco Trust Under Agreement Dated February 28, 1996sold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DYAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.